Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00288574 · ClinicalTrials.gov registry record · Phase 4
Fluoxetine to Prevent Relapse and Enhance Psychological Recovery in Women With Anorexia Nervosa
A Phase 4 study of Anorexia Nervosa and Eating Disorders, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 4
- Development phase
- 93
- Enrollment target
- 1
- Study location
NCT00288574: Completed Phase 4 study of Anorexia Nervosa and Eating Disorders, sponsored by New York State Psychiatric Institute.
NCT00288574 is a Phase 4 study of Anorexia Nervosa and Eating Disorders that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 93 participants, below the 948-participant average among 43 other Anorexia Nervosa trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00288574, a Phase 4 study of Anorexia Nervosa and Eating Disorders, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 93 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the effectiveness of fluoxetine versus placebo in reducing the rate of relapse of anorexia nervosa (AN) and enhancing the psychosocial and behavioral recovery of people who have been treated for AN.
Primary Outcome
The primary outcome measure was the proportion of patients with AN successfully completing 1 year of treatment and maintaining \> 85% Ideal Body Weight.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Fluoxetine
Study Locations (1)
New York
- New York State Psychiatric Institute/Columbia University Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2000-01 |
| Est. Completion | 2005-05 |
| Phase | Phase 4 |
What the finished NCT00288574 record still lists
NCT00288574 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 93 participants, a relatively small participant target, below the 948-participant average among 43 other Anorexia Nervosa trials with a reported enrollment target (90% lower).
The record links to 2 conditions, with Anorexia Nervosa appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00288574 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00288574 about?
NCT00288574 is a clinical study titled "Fluoxetine to Prevent Relapse and Enhance Psychological Recovery in Women With Anorexia Nervosa". This study will evaluate the effectiveness of fluoxetine versus placebo in reducing the rate of relapse of anorexia nervosa (AN) and enhancing the psychosocial and behavioral recovery of people who have been treated for AN.
What is the current status of trial NCT00288574?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 93 participants. The study started on 2000-01. Estimated completion is 2005-05.
What conditions does trial NCT00288574 study?
This clinical trial studies the following conditions: Anorexia Nervosa, Eating Disorders.
What interventions are being tested in trial NCT00288574?
The interventions under investigation include: Placebo (DRUG), Fluoxetine (DRUG).
Who is sponsoring clinical trial NCT00288574?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00288574 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anorexia Nervosa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00288574's enrollment target sits among peer trials
93 10th of 43 higher than 34 of 43 other Anorexia Nervosa trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anorexia Nervosa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Metabolic Diet for Relapse Prevention in Anorexia Nervosa
RECRUITING · NA
-
Facing Eating Disorder Fears for Anorexia Nervosa
RECRUITING · NA
-
Therapeutic Ketogenic Diet in Anorexia Nervosa
RECRUITING · NA
-
Confirming the Effectiveness of Online Guided Self-Help Family-Based Treatment for Adolescent Anorexia Nervosa
RECRUITING · NA
-
Eating Disorders Genetics Initiative 2
RECRUITING
-
Incentive Processing and Learning in Anorexia Nervosa and Bulimia Nervosa
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02203526 · 93 participants · Phase 1
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
- NCT03089554 · 93 participants · Phase 2
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
- NCT05000021 · 93 participants · NA
Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes
- NCT05489887 · 93 participants · Phase 2
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia